{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:04:54Z","timestamp":1792159494764,"version":"4.4.0"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R44 CA203166-02"],"award-info":[{"award-number":["R44 CA203166-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bonr.2018.06.007","type":"journal-article","created":{"date-parts":[[2018,7,2]],"date-time":"2018-07-02T21:26:37Z","timestamp":1530566797000},"page":"47-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":180,"special_numbering":"C","title":["Bisphosphonate conjugation for bone specific drug targeting"],"prefix":"10.1016","volume":"9","author":[{"given":"Kristen B.","family":"Farrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Karpeisky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas H.","family":"Thamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0426-900X","authenticated-orcid":false,"given":"Shawn","family":"Zinnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.bonr.2018.06.007_bb0005","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1016\/j.bmcl.2013.09.043","article-title":"Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma","volume":"23","author":"Agyin","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"15","key":"10.1016\/j.bonr.2018.06.007_bb0010","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1016\/j.bmcl.2009.05.117","article-title":"Synthesis of calcium phosphate-binding liposome for drug delivery","volume":"19","author":"Anada","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0015","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.bmc.2012.01.024","article-title":"Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis","volume":"20","author":"Arns","year":"2012","journal-title":"Bioorg. Med. Chem."},{"issue":"11","key":"10.1016\/j.bonr.2018.06.007_bb0020","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/jps.20186","article-title":"A di(bisphosphonic acid) for protein coupling and targeting to bone","volume":"93","author":"Bansal","year":"2004","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00132-008-1404-4","article-title":"Current diagnosis and therapy of osteoporosis on the basis of \"European guidance 2008\"","volume":"38","author":"Bartl","year":"2009","journal-title":"Orthopade"},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0030","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s002239900104","article-title":"Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats","volume":"59","author":"Bauss","year":"1996","journal-title":"Calcif. Tissue Int."},{"issue":"10","key":"10.1016\/j.bonr.2018.06.007_bb0035","first-page":"961","article-title":"Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. I. Synthesis and distribution in animals","volume":"21","author":"Bevan","year":"1980","journal-title":"J. Nucl. Med."},{"issue":"1\u20132","key":"10.1016\/j.bonr.2018.06.007_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijpharm.2010.04.015","article-title":"Synthesis, characterization and in vitro evaluation of a bone targeting delivery system for salmon calcitonin","volume":"394","author":"Bhandari","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2011.09.096","article-title":"Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats","volume":"158","author":"Bhandari","year":"2012","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.bonr.2018.06.007_bb0050","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1021\/bc500614b","article-title":"Novel pullulan bioconjugate for selective breast cancer bone metastases treatment","volume":"26","author":"Bonzi","year":"2015","journal-title":"Bioconjug. Chem."},{"issue":"16","key":"10.1016\/j.bonr.2018.06.007_bb0060","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0065","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/jvim.14257","article-title":"Downregulation of CXCR4 expression and functionality after zoledronate exposure in canine osteosarcoma","volume":"30","author":"Byrum","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.bonr.2018.06.007_bb0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejmech.2012.07.053","article-title":"Bone-targeting glycol and NSAIDS ester prodrugs of rhein: synthesis, hydroxyapatite affinity, stability, anti-inflammatory, ulcerogenicity index and pharmacokinetics studies","volume":"55","author":"Cai","year":"2012","journal-title":"Eur. J. Med. Chem."},{"issue":"41","key":"10.1016\/j.bonr.2018.06.007_bb0075","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1038\/sj.onc.1207814","article-title":"The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate","volume":"23","author":"Caraglia","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0080","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1172\/JCI114459","article-title":"Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro","volume":"85","author":"Carano","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.nano.2016.08.015","article-title":"Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties","volume":"e13","author":"Carbone","year":"2017","journal-title":"Nanomedicine"},{"issue":"10","key":"10.1016\/j.bonr.2018.06.007_bb0090","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.biomaterials.2007.12.022","article-title":"Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate","volume":"29","author":"Cenni","year":"2008","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0095","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/cbdd.12194","article-title":"Synthesis, biological evaluation and molecular docking studies of high-affinity bone targeting N,N(') -bis (alendronate) diethylenetriamene-N,N'-triacetic acid: a bifunctional bone scintigraphy agent","volume":"82","author":"Chadha","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0100","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1021\/acs.bioconjchem.5b00160","article-title":"Determination of the rat in vivo pharmacokinetic profile of a bone-targeting dual-action pro-drug for treatment of osteoporosis","volume":"26","author":"Chen","year":"2015","journal-title":"Bioconjug. Chem."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0105","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/pbc.20019","article-title":"Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines","volume":"42","author":"Cheng","year":"2004","journal-title":"Pediatr. Blood Cancer"},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jconrel.2007.06.003","article-title":"Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone","volume":"122","author":"Choi","year":"2007","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0115","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1021\/mp2001445","article-title":"Dendritic poly(ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms","volume":"8","author":"Clementi","year":"2011","journal-title":"Mol. Pharm."},{"issue":"Pt A","key":"10.1016\/j.bonr.2018.06.007_bb0120","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2015.10.005","article-title":"Targeted delivery to bone and mineral deposits using bisphosphonate ligands","volume":"99","author":"Cole","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"20 Pt 2","key":"10.1016\/j.bonr.2018.06.007_bb0125","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.bonr.2018.06.007_bb0130","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1021\/jm049874c","article-title":"Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis","volume":"47","author":"Coleman","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bonr.2018.06.007_bb0135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13569-016-0046-2","article-title":"Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients","volume":"6","author":"Conry","year":"2016","journal-title":"Clin. Sarcoma Res."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0140","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"Corey","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bonr.2018.06.007_bb0145","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2013.10.004","article-title":"Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy","volume":"58","author":"Cornelis","year":"2014","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0150","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","article-title":"Recent advances in understanding the mechanism of action of bisphosphonates","volume":"6","author":"Coxon","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","article-title":"Pharmacology of bisphosphonates","volume":"49","author":"Cremers","year":"2011","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0160","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J. Bone Miner. Res."},{"issue":"3 Suppl","key":"10.1016\/j.bonr.2018.06.007_bb0165","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cncr.11125","article-title":"Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease","volume":"97","author":"Croucher","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17030428","article-title":"Targeted delivery systems for molecular therapy in skeletal disorders","volume":"17","author":"Dang","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"12 Pt 1","key":"10.1016\/j.bonr.2018.06.007_bb0175","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1158\/1535-7163.MCT-07-0546","article-title":"Zoledronic acid inhibits osteosarcoma growth in an orthotopic model","volume":"6","author":"Dass","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0180","first-page":"4141","article-title":"Treatment of bone metastasis in prostate cancer: efficacy of a novel polybisphosphonate","volume":"31","author":"Daubine","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bonr.2018.06.007_bb0185","doi-asserted-by":"crossref","first-page":"637976","DOI":"10.1155\/2013\/637976","article-title":"Bisphosphonates and cancer: what opportunities from nanotechnology?","volume":"2013","author":"De Rosa","year":"2013","journal-title":"J. Drug Deliv."},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0190","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0195","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1148\/radiology.136.1.6446106","article-title":"99mTc-hydroxymethane diphosphonate: a new bone imaging agent with a low tin content","volume":"136","author":"Domstad","year":"1980","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0200","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3892\/or.2013.2907","article-title":"In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma","volume":"31","author":"Dos Santos","year":"2014","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0205","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1021\/mp8002368","article-title":"Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis","volume":"6","author":"Doschak","year":"2009","journal-title":"Mol. Pharm."},{"issue":"20","key":"10.1016\/j.bonr.2018.06.007_bb0210","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2011.37.4546","article-title":"Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group","volume":"30","author":"Ebb","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0215","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.apradiso.2004.10.004","article-title":"188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases","volume":"62","author":"El-Mabhouh","year":"2005","journal-title":"Appl. Radiat. Isot."},{"issue":"7","key":"10.1016\/j.bonr.2018.06.007_bb0220","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00259-008-0728-y","article-title":"188Re-labelled gemcitabine\/bisphosphonate (Gem\/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases","volume":"35","author":"El-Mabhouh","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0225","first-page":"627","article-title":"Preclinical investigations of drug and radionuclide conjugates of bisphosphonates for the treatment of metastatic bone cancer","volume":"19","author":"El-Mabhouh","year":"2004","journal-title":"Cancer Biother. Radiopharm."},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0230","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.nucmedbio.2006.06.004","article-title":"A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer","volume":"33","author":"El-Mabhouh","year":"2006","journal-title":"Nucl. Med. Biol."},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0235","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3727\/096504011X13021877989874","article-title":"A conjugate of gemcitabine with bisphosphonate (Gem\/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases","volume":"19","author":"El-Mabhouh","year":"2011","journal-title":"Oncol. Res."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0240","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.bmcl.2007.11.029","article-title":"Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation","volume":"18","author":"Erez","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0245","first-page":"431","article-title":"Single-agent pamidronate for palliative therapy of canine appendicular osteosarcoma bone pain","volume":"21","author":"Fan","year":"2007","journal-title":"J. Vet. Intern. Med."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0250","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1939-1676.2008.0046.x","article-title":"The bone biologic effects of zoledronate in healthy dogs and dogs with malignant osteolysis","volume":"22","author":"Fan","year":"2008","journal-title":"J. Vet. Intern. Med."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0255","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1939-1676.2008.0221.x","article-title":"Double-blind placebo-controlled trial of adjuvant pamidronate with palliative radiotherapy and intravenous doxorubicin for canine appendicular osteosarcoma bone pain","volume":"23","author":"Fan","year":"2009","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.bonr.2018.06.007_bb0260","doi-asserted-by":"crossref","first-page":"421746","DOI":"10.1155\/2015\/421746","article-title":"Biology of bone tissue: structure, function, and factors that influence bone cells","volume":"2015","author":"Florencio-Silva","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0265","first-page":"1371","article-title":"Involvement of the mevalonate pathway in the antiproliferative effect of zoledronate on ACHN renal cell carcinoma cells","volume":"27","author":"Fujita","year":"2012","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0270","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0968-0896(99)00045-0","article-title":"Prostaglandin E2-bisphosphonate conjugates: potential agents for treatment of osteoporosis","volume":"7","author":"Gil","year":"1999","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.bonr.2018.06.007_bb0275","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.addr.2004.12.015","article-title":"Designing proteins for bone targeting","volume":"57","author":"Gittens","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0280","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1021\/mp050017u","article-title":"Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes","volume":"2","author":"Gittens","year":"2005","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bonr.2018.06.007_bb0285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coph.2016.02.013","article-title":"New approaches to targeting the bone marrow microenvironment in multiple myeloma","volume":"28","author":"Gooding","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0290","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ijc.24758","article-title":"The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation","volume":"126","author":"Guenther","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0295","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/mabi.201000205","article-title":"The synthesis of a multiblock osteotropic polyrotaxane by copper(I)-catalyzed huisgen 1,3-dipolar cycloaddition","volume":"10","author":"Hein","year":"2010","journal-title":"Macromol. Biosci."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0300","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jtho.2015.10.001","article-title":"Effect of bisphosphonates, Denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung Cancer and bone metastases: a systematic review","volume":"11","author":"Hendriks","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.bonr.2018.06.007_bb0305","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1021\/jm0105326","article-title":"Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials","volume":"45","author":"Herczegh","year":"2002","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0310","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","article-title":"Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma","volume":"37","author":"Heymann","year":"2005","journal-title":"Bone"},{"issue":"15","key":"10.1016\/j.bonr.2018.06.007_bb0315","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2165\/00003088-200342150-00002","article-title":"Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents","volume":"42","author":"Hirabayashi","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"1\u20132","key":"10.1016\/j.bonr.2018.06.007_bb0320","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0168-3659(00)00355-2","article-title":"Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the osteotropic drug delivery system (ODDS)","volume":"70","author":"Hirabayashi","year":"2001","journal-title":"J. Control. Release"},{"issue":"8","key":"10.1016\/j.bonr.2018.06.007_bb0325","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/bdd.323","article-title":"Dose-dependent pharmacokinetics and disposition of bisphosphonic prodrug of diclofenac based on osteotropic drug delivery system (ODDS)","volume":"23","author":"Hirabayashi","year":"2002","journal-title":"Biopharm. Drug Dispos."},{"issue":"17","key":"10.1016\/j.bonr.2018.06.007_bb0330","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1021\/jm300493m","article-title":"Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix","volume":"55","author":"Hochdorffer","year":"2012","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0335","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3892\/ijo_00000705","article-title":"Development of a novel poly bisphosphonate conjugate for treatment of skeletal metastasis and osteoporosis","volume":"37","author":"Holmberg","year":"2010","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0340","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/cmmi.1606","article-title":"Gallium(III) complexes of NOTA-bis (phosphonate) conjugates as PET radiotracers for bone imaging","volume":"10","author":"Holub","year":"2015","journal-title":"Contrast Media Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0345","first-page":"105","article-title":"Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gem-bisphosphonate conjugate of methotrexate","volume":"37","author":"Hosain","year":"1996","journal-title":"J. Nucl. Med."},{"issue":"21","key":"10.1016\/j.bonr.2018.06.007_bb0350","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1021\/jm801007z","article-title":"Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis","volume":"51","author":"Houghton","year":"2008","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bonr.2018.06.007_bb0355","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2014.3634","article-title":"Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid","volume":"174","author":"Hue","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0360","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1517\/17425240903280422","article-title":"Strategies for the targeted delivery of therapeutics for osteosarcoma","volume":"6","author":"Hughes","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0365","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1172\/JCI114100","article-title":"Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow","volume":"83","author":"Hughes","year":"1989","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0370","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0378-5173(99)00256-2","article-title":"Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice","volume":"190","author":"Ishida","year":"1999","journal-title":"Int. J. Pharm."},{"issue":"48","key":"10.1016\/j.bonr.2018.06.007_bb0375","doi-asserted-by":"crossref","first-page":"14575","DOI":"10.1002\/anie.201507064","article-title":"A general strategy for targeting drugs to bone","volume":"54","author":"Jahnke","year":"2015","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0380","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cellbi.2008.11.011","article-title":"Docetaxel\/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells","volume":"33","author":"Karabulut","year":"2009","journal-title":"Cell Biol. Int."},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0385","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/bc800369c","article-title":"Fluorescently labeled risedronate and related analogues: \"magic linker\" synthesis","volume":"19","author":"Kashemirov","year":"2008","journal-title":"Bioconjug. Chem."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0390","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1359\/jbmr.2000.15.5.936","article-title":"Selective drug delivery system to bone: small peptide (Asp)6 conjugation","volume":"15","author":"Kasugai","year":"2000","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0395","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF01612916","article-title":"Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?","volume":"116","author":"Klenner","year":"1990","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0400","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jbo.2013.09.001","article-title":"Incidence, consequences and treatment of bone metastases in breast cancer patients-experience from a single cancer centre","volume":"2","author":"Kuchuk","year":"2013","journal-title":"J. Bone Oncol."},{"issue":"10","key":"10.1016\/j.bonr.2018.06.007_bb0405","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-08-1616","article-title":"Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model","volume":"15","author":"Labrinidis","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bonr.2018.06.007_bb0410","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2016.08.002","article-title":"Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases","volume":"91","author":"Lange","year":"2016","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0415","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jbm.b.31500","article-title":"Differences between bisphosphonates in binding affinities for hydroxyapatite","volume":"92","author":"Lawson","year":"2010","journal-title":"J Biomed Mater Res B Appl Biomater"},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0420","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1021\/mp200045p","article-title":"Role of prostaglandin pathway and alendronate-based carriers to enhance statin-induced bone","volume":"8","author":"Lee","year":"2011","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0425","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jconrel.2007.06.021","article-title":"Novel biomineral-binding cyclodextrins for controlled drug delivery in the oral cavity","volume":"122","author":"Liu","year":"2007","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0430","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jconrel.2011.09.090","article-title":"Preparation of polymer-based multimodal imaging agent to visualize the process of bone regeneration","volume":"157","author":"Liu","year":"2012","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0435","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jbmr.2382","article-title":"Novel EP4 receptor agonist-bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the ovariectomized rat model of postmenopausal bone loss","volume":"30","author":"Liu","year":"2015","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0440","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1148\/rg.232025103","article-title":"Radionuclide bone imaging: an illustrative review","volume":"23","author":"Love","year":"2003","journal-title":"Radiographics"},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0445","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.addr.2012.01.012","article-title":"Targeting polymer therapeutics to bone","volume":"64","author":"Low","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0450","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/jbmr.5650030210","article-title":"Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate","volume":"3","author":"Lowik","year":"1988","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0455","first-page":"581","article-title":"Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice","volume":"20","author":"Lu","year":"2008","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0460","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2012.04.038","article-title":"Macromolecular therapeutics in cancer treatment: the EPR effect and beyond","volume":"164","author":"Maeda","year":"2012","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0465","first-page":"259","article-title":"Bone scintigraphy and metabolic disorders","volume":"43","author":"Mari","year":"1999","journal-title":"Q. J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0470","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/8756-3282(96)00182-2","article-title":"Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones","volume":"19","author":"Masarachia","year":"1996","journal-title":"Bone"},{"issue":"18","key":"10.1016\/j.bonr.2018.06.007_bb0475","first-page":"5381","article-title":"Significance of blood vessel leakiness in cancer","volume":"62","author":"McDonald","year":"2002","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.bonr.2018.06.007_bb0480","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.nucmedbio.2016.07.009","article-title":"A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting","volume":"43","author":"Meckel","year":"2016","journal-title":"Nucl. Med. Biol."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0485","first-page":"281","article-title":"Polymer-conjugated guanidine is a potentially useful anti-tumor agent","volume":"35","author":"Meurling","year":"2009","journal-title":"Int. J. Oncol."},{"issue":"8","key":"10.1016\/j.bonr.2018.06.007_bb0490","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cncr.25744","article-title":"Addition of pamidronate to chemotherapy for the treatment of osteosarcoma","volume":"117","author":"Meyers","year":"2011","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.bonr.2018.06.007_bb0495","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1002\/anie.200805133","article-title":"Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate","volume":"48","author":"Miller","year":"2009","journal-title":"Angew. Chem. Int. Ed. Eng."},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0500","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1021\/mp200083n","article-title":"Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model","volume":"8","author":"Miller","year":"2011","journal-title":"Mol. Pharm."},{"issue":"15","key":"10.1016\/j.bonr.2018.06.007_bb0505","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1016\/j.biomaterials.2013.01.052","article-title":"Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases","volume":"34","author":"Miller","year":"2013","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0510","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bmc.2009.12.041","article-title":"Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens","volume":"18","author":"Morioka","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0515","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/adhm.201300465","article-title":"Osteotropic therapy via targeted layer-by-layer nanoparticles","volume":"3","author":"Morton","year":"2014","journal-title":"Adv. Healthc. Mater."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0520","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2362.1971.tb00640.x","article-title":"The effects of diphosphonates, polyphosphates, and calcitonin on \"immobilisation osteoporosis\" in rats","volume":"1","author":"Muhlbauer","year":"1971","journal-title":"Eur. J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.bonr.2018.06.007_bb0525","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/cas.12448","article-title":"Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan oncology group","volume":"105","author":"Murakami","year":"2014","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0530","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1248\/cpb.59.710","article-title":"Dialkyl bisphosphonate platinum(II) complex as a potential drug for metastatic bone tumor","volume":"59","author":"Nakatake","year":"2011","journal-title":"Chem. Pharm. Bull.(Tokyo)"},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0535","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/ijc.11397","article-title":"Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth","volume":"107","author":"Neudert","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"19","key":"10.1016\/j.bonr.2018.06.007_bb0540","doi-asserted-by":"crossref","first-page":"7610","DOI":"10.1158\/0008-5472.CAN-09-4272","article-title":"Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients","volume":"70","author":"Odri","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bonr.2018.06.007_bb0545","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1471-2407-14-169","article-title":"Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration","volume":"14","author":"Odri","year":"2014","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0550","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/jbmr.2182","article-title":"Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL","volume":"29","author":"Ohba","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2018.06.007_bb0555","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bone.2014.03.005","article-title":"Pleiotropic effects of bisphosphonates on osteosarcoma","volume":"63","author":"Ohba","year":"2014","journal-title":"Bone"},{"issue":"11","key":"10.1016\/j.bonr.2018.06.007_bb0560","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1021\/jo800317e","article-title":"Bisphosphonate derivatives of nucleoside antimetabolites: hydrolytic stability and hydroxyapatite adsorption of 5\u2032-beta,gamma-methylene and 5\u2032-beta,gamma-(1-hydroxyethylidene) triphosphates of 5-fluorouridine and ara-cytidine","volume":"73","author":"Ora","year":"2008","journal-title":"J. Organomet. Chem."},{"issue":"11","key":"10.1016\/j.bonr.2018.06.007_bb0565","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1002\/cncr.21530","article-title":"Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice","volume":"104","author":"Ory","year":"2005","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0570","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/jor.22714","article-title":"Osteoclast inhibition impairs chondrosarcoma growth and bone destruction","volume":"32","author":"Otero","year":"2014","journal-title":"J. Orthop. Res."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0575","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1078-1439(03)00013-9","article-title":"Chromosome 18 suppresses prostate cancer metastases","volume":"21","author":"Padalecki","year":"2003","journal-title":"Urol. Oncol."},{"issue":"11","key":"10.1016\/j.bonr.2018.06.007_bb0580","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1021\/jo001489h","article-title":"Novel synthesis of bis(phosphonic acid)-steroid conjugates","volume":"66","author":"Page","year":"2001","journal-title":"J. Organomet. Chem."},{"issue":"7","key":"10.1016\/j.bonr.2018.06.007_bb0585","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/mabi.200700338","article-title":"Release of prostaglandin E(1) from N-(2-hydroxypropyl)methacrylamide copolymer conjugates by bone cells","volume":"8","author":"Pan","year":"2008","journal-title":"Macromol. Biosci."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0590","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bone.2011.01.003","article-title":"Safety of bisphosphonates","volume":"49","author":"Pazianas","year":"2011","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0595","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1185\/030079902125000543","article-title":"The role of bisphosphonates in breast cancer management: review article","volume":"18","author":"Pickering","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0600","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/jfb3010079","article-title":"Synthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic properties","volume":"3","author":"Pignatello","year":"2012","journal-title":"J. Funct. Biomater."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0605","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/jre.12036","article-title":"Effects of local simvastatin-alendronate conjugate in preventing periodontitis bone loss","volume":"48","author":"Price","year":"2013","journal-title":"J. Periodontal Res."},{"issue":"11","key":"10.1016\/j.bonr.2018.06.007_bb0610","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/jpm.2009.9936","article-title":"Toxicity of bisphosphonates","volume":"12","author":"Prommer","year":"2009","journal-title":"J. Palliat. Med."},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0615","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jconrel.2011.11.020","article-title":"Bone metastasis targeting: a novel approach to reach bone using zoledronate anchored PLGA nanoparticle as carrier system loaded with docetaxel","volume":"158","author":"Ramanlal Chaudhari","year":"2012","journal-title":"J. Control. Release"},{"issue":"1\u20132","key":"10.1016\/j.bonr.2018.06.007_bb0620","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijpharm.2016.04.049","article-title":"Revisiting bone targeting potential of novel hydroxyapatite based surface modified PLGA nanoparticles of risedronate: pharmacokinetic and biochemical assessment","volume":"506","author":"Rawat","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0625","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/cmdc.200800255","article-title":"Bisphosphonated benzoxazinorifamycin prodrugs for the prevention and treatment of osteomyelitis","volume":"3","author":"Reddy","year":"2008","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0630","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bone.2010.03.006","article-title":"A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites","volume":"47","author":"Reinholz","year":"2010","journal-title":"Bone"},{"issue":"20 Pt 2","key":"10.1016\/j.bonr.2018.06.007_bb0635","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bonr.2018.06.007_bb0640","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1479-5876-9-177","article-title":"Tumour macrophages as potential targets of bisphosphonates","volume":"9","author":"Rogers","year":"2011","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0645","first-page":"1851","article-title":"Synergistic growth inhibition of PC3 prostate cancer cells with low-dose combinations of simvastatin and alendronate","volume":"35","author":"Rogers","year":"2015","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0650","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/jbm.a.33165","article-title":"Binding affinity of surface functionalized gold nanoparticles to hydroxyapatite","volume":"99","author":"Ross","year":"2011","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0655","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: the first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0660","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/pbc.22821","article-title":"A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent\/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study","volume":"57","author":"Russell","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"issue":"11","key":"10.1016\/j.bonr.2018.06.007_bb0665","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.bonr.2018.06.007_bb0670","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/156800910793605767","article-title":"Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases","volume":"10","author":"Salerno","year":"2010","journal-title":"Curr. Cancer Drug Targets"},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0675","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14712598.6.12.1333","article-title":"Zoledronic acid in the management of metastatic bone disease","volume":"6","author":"Santini","year":"2006","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"15 Pt 1","key":"10.1016\/j.bonr.2018.06.007_bb0680","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Santini","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0685","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.bbrc.2005.09.198","article-title":"Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro","volume":"338","author":"Schindeler","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.bonr.2018.06.007_bb0690","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1016\/j.bmc.2011.04.015","article-title":"N(4)-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate)","volume":"19","author":"Schott","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0695","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1007\/s10637-011-9688-3","article-title":"Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay","volume":"30","author":"Schott","year":"2012","journal-title":"Investig. New Drugs"},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0700","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1021\/acs.jmedchem.6b01615","article-title":"Design, synthesis, and antimicrobial evaluation of a novel bone-targeting bisphosphonate-ciprofloxacin conjugate for the treatment of osteomyelitis biofilms","volume":"60","author":"Sedghizadeh","year":"2017","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bonr.2018.06.007_bb0705","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005233","article-title":"Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics","volume":"4","author":"Segal","year":"2009","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.bonr.2018.06.007_bb0710","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1016\/j.biomaterials.2011.02.059","article-title":"Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances","volume":"32","author":"Segal","year":"2011","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0715","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s10495-008-0211-z","article-title":"The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis","volume":"13","author":"Sewing","year":"2008","journal-title":"Apoptosis"},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0720","first-page":"729","article-title":"Novel bone-targeted Src tyrosine kinase inhibitor drug discovery","volume":"6","author":"Shakespeare","year":"2003","journal-title":"Curr. Opin. Drug Discov. Devel."},{"issue":"10","key":"10.1016\/j.bonr.2018.06.007_bb0725","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074402","article-title":"Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey","volume":"8","author":"Silvestris","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0730","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM198002073020602","article-title":"Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma","volume":"302","author":"Siris","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0735","first-page":"377","article-title":"Tetracyclines and mineralized tissues: review and perspectives","volume":"48","author":"Skinner","year":"1975","journal-title":"Yale J. Biol. Med."},{"issue":"11","key":"10.1016\/j.bonr.2018.06.007_bb0740","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"7014","key":"10.1016\/j.bonr.2018.06.007_bb0745","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0750","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1748-5827.2008.00635.x","article-title":"Zoledronic acid for the treatment of appendicular osteosarcoma in a dog","volume":"50","author":"Spugnini","year":"2009","journal-title":"J. Small Anim. Pract."},{"issue":"9","key":"10.1016\/j.bonr.2018.06.007_bb0755","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00264-010-1130-5","article-title":"Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78","volume":"35","author":"Streitbuerger","year":"2011","journal-title":"Int. Orthop."},{"key":"10.1016\/j.bonr.2018.06.007_bb0760","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/0223-5234(92)90117-J","article-title":"Study of the delivery-targeting concept applied to antineoplasic drugs active on human osteosarcoma. I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues","volume":"27","author":"Sturtz","year":"1992","journal-title":"Eur. J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bonr.2018.06.007_bb0765","first-page":"744","article-title":"Technetium-99m-methylene diphosphonate\u2013a superior agent for skeletal imaging: comparison with other technetium complexes","volume":"16","author":"Subramanian","year":"1975","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0770","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1021\/acs.bioconjchem.5b00369","article-title":"Fluorescent bisphosphonate and carboxyphosphonate probes: a versatile imaging toolkit for applications in bone biology and biomedicine","volume":"27","author":"Sun","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"28","key":"10.1016\/j.bonr.2018.06.007_bb0775","doi-asserted-by":"crossref","first-page":"10287","DOI":"10.1073\/pnas.1401337111","article-title":"Engineered nanomedicine for myeloma and bone microenvironment targeting","volume":"111","author":"Swami","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.bonr.2018.06.007_bb0780","doi-asserted-by":"crossref","first-page":"9217","DOI":"10.1016\/j.bmc.2008.09.010","article-title":"Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis","volume":"16","author":"Tanaka","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0785","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.4049\/jimmunol.1201460","article-title":"A polyglutamic acid motif confers IL-27 hydroxyapatite and bone-binding properties","volume":"190","author":"Tormo","year":"2013","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0790","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1021\/bc100071k","article-title":"188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases","volume":"21","author":"Torres Martin de Rosales","year":"2010","journal-title":"Bioconjug. Chem."},{"issue":"6","key":"10.1016\/j.bonr.2018.06.007_bb0795","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1530\/EJE-11-0454","article-title":"Denosumab for bone diseases: translating bone biology into targeted therapy","volume":"165","author":"Tsourdi","year":"2011","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0800","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jcb.25291","article-title":"Biology and treatment of Paget's disease of bone","volume":"117","author":"Vallet","year":"2016","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bonr.2018.06.007_bb0805","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pharmthera.2015.11.008","article-title":"Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials","volume":"158","author":"Van Acker","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0810","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S8756-3282(98)00120-3","article-title":"Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships","volume":"23","author":"van Beek","year":"1998","journal-title":"Bone"},{"issue":"25","key":"10.1016\/j.bonr.2018.06.007_bb0815","doi-asserted-by":"crossref","first-page":"8781","DOI":"10.1021\/ja902857b","article-title":"In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach","volume":"131","author":"Varghese","year":"2009","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0820","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/bc0001600","article-title":"Development of a conjugate of (99m)Tc-EC with aminomethylenediphosphonate in the search for a bone tracer with fast clearance from soft tissue","volume":"13","author":"Verbeke","year":"2002","journal-title":"Bioconjug. Chem."},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0825","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S8756-3282(00)00427-0","article-title":"Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption","volume":"28","author":"Violette","year":"2001","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0830","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/jm7012776","article-title":"Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy","volume":"51","author":"Vitha","year":"2008","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0835","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.addr.2011.09.002","article-title":"RNA therapeutics targeting osteoclast-mediated excessive bone resorption","volume":"64","author":"Wang","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.bonr.2018.06.007_bb0840","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.addr.2004.12.011","article-title":"Bone-targeting macromolecular therapeutics","volume":"57","author":"Wang","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0845","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/jbm.a.34002","article-title":"Bisphosphonate-decorated lipid nanoparticles designed as drug carriers for bone diseases","volume":"100","author":"Wang","year":"2012","journal-title":"J. Biomed. Mater. Res. A"},{"issue":"7","key":"10.1016\/j.bonr.2018.06.007_bb0850","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1039\/c4bm00020j","article-title":"Peptide decoration of nanovehicles to achieve active targeting and pathology-responsive cellular uptake for bone metastasis chemotherapy","volume":"2","author":"Wang","year":"2014","journal-title":"Biomater. Sci."},{"issue":"10","key":"10.1016\/j.bonr.2018.06.007_bb0855","first-page":"4299","article-title":"Cytostatic activity of a 5-fluoro-2\u2032-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines","volume":"32","author":"Weinreich","year":"2012","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0860","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0865","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0870","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.biomaterials.2005.06.012","article-title":"A comparison of mineral affinity of bisphosphonate-protein conjugates constructed with disulfide and thioether linkages","volume":"27","author":"Wright","year":"2006","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.bonr.2018.06.007_bb0875","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10544-011-9626-3","article-title":"Methylene diphosphonate-conjugated adriamycin liposomes: preparation, characteristics, and targeted therapy for osteosarcomas in vitro and in vivo","volume":"14","author":"Wu","year":"2012","journal-title":"Biomed. Microdevices"},{"issue":"21","key":"10.1016\/j.bonr.2018.06.007_bb0880","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1016\/j.biomaterials.2013.03.053","article-title":"Hydroxyapatite-anchored dendrimer for in situ remineralization of human tooth enamel","volume":"34","author":"Wu","year":"2013","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.bonr.2018.06.007_bb0885","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2013.09.008","article-title":"Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002\u20132012","volume":"57","author":"Wysowski","year":"2013","journal-title":"Bone"},{"issue":"15","key":"10.1016\/j.bonr.2018.06.007_bb0890","first-page":"2116","article-title":"Targeted antiosteosarcoma methotrexate-bisphosphonate conjugate induces apoptosis of osteosarcoma cells in vitro","volume":"18","author":"Yang","year":"2014","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0895","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s11095-013-1237-7","article-title":"Synthesis, characterization and biodistribution studies of (125)I-radioiodinated di-PEGylated bone targeting salmon calcitonin analogue in healthy rats","volume":"31","author":"Yang","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bonr.2018.06.007_bb0900","doi-asserted-by":"crossref","first-page":"14614","DOI":"10.1038\/srep14614","article-title":"Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer","volume":"5","author":"Ye","year":"2015","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0905","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/j.biomaterials.2013.01.059","article-title":"Bifunctional bisphosphonates for delivering PTH (1-34) to bone mineral with enhanced bioactivity","volume":"34","author":"Yewle","year":"2013","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.bonr.2018.06.007_bb0910","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1073\/pnas.062053399","article-title":"Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation","volume":"99","author":"Yoshida","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.bonr.2018.06.007_bb0915","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nbt1201-1148","article-title":"In vivo near-infrared fluorescence imaging of osteoblastic activity","volume":"19","author":"Zaheer","year":"2001","journal-title":"Nat. Biotechnol."},{"issue":"38","key":"10.1016\/j.bonr.2018.06.007_bb0920","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1016\/j.biomaterials.2014.09.007","article-title":"Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy","volume":"35","author":"Zhan","year":"2014","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.bonr.2018.06.007_bb0925","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1021\/bm050273s","article-title":"Cleavage of disulfide-linked fetuin-bisphosphonate conjugates with three physiological thiols","volume":"6","author":"Zhang","year":"2005","journal-title":"Biomacromolecules"},{"issue":"1","key":"10.1016\/j.bonr.2018.06.007_bb0930","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jbo.2012.11.002","article-title":"The role of the bone microenvironment in skeletal metastasis","volume":"2","author":"Zheng","year":"2013","journal-title":"J. Bone Oncol."},{"issue":"suppl","key":"10.1016\/j.bonr.2018.06.007_bb0935","article-title":"Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate cytosine arabinoside (MBC-11), in cancer patients with bone metastases","volume":"35","author":"Zinnen","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235218721830041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235218721830041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T16:17:46Z","timestamp":1762445866000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235218721830041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":187,"alternative-id":["S235218721830041X"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2018.06.007","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bisphosphonate conjugation for bone specific drug targeting","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2018.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}